Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
Active, not recruiting · NCT05043688 · Registry updated 2026-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | Resectable Esophageal Squamous Cell Carcinoma | Active, not recruiting | Phase 3 | 2026-09-17 | NCT05043688 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. | 132 |
| Zhigang Li | 3 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Anhui Provincial Hospital | Hefei | China | 34 |
| Anyang Tumour Hospital | Anyang | China | 3 |
| Shanghai Chest Hospital | Shanghai | China | 11 |
| Sun Yat-Sen University Cancer Center | Guangzhou | China | 66 |
| Zhongshan Hospital of Fudan University | Shanghai | China | 6 |